Welcome to our dedicated page for Alphatec Hldgs SEC filings (Ticker: ATEC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Alphatec Holdings, Inc. filings document the reporting record of a spine-focused medical technology company. Its Form 8-K disclosures include quarterly and annual operating results, surgical and EOS revenue commentary, non-GAAP profitability measures, preliminary financial information and related press-release exhibits.
The company’s regulatory filings also cover material financing agreements, including senior secured credit facilities, revolving borrowing capacity, term-loan arrangements and references to convertible senior notes. Proxy and governance filings document director elections, board composition, executive and director compensation, equity awards, committee matters and other shareholder voting disclosures.
Sponsel David reported acquisition or exercise transactions in this Form 4 filing.
Alphatec Holdings EVP of Sales David Sponsel reported multiple equity awards from the company. On February 25, 2026, he was awarded 205,094 restricted stock units (RSUs) tied to a prior performance-based award for the fiscal year ended December 31, 2025, vesting in three equal installments on March 5 of 2026, 2027, and 2028.
He also received 93,410 RSUs vesting in three equal installments on March 5 of 2027, 2028, and 2029, plus 20,380 RSUs granted in lieu of a portion of his 2025 cash bonus that vest on December 4, 2026. In addition, Sponsel was granted up to 46,705 performance-based RSUs that vest only if Alphatec’s common stock reaches 30‑day average prices of at least $25.00 or $36.00 per share by specified dates, or if certain operational metrics determined by the compensation committee are achieved.
Koning John Todd reported acquisition or exercise transactions in this Form 4 filing.
Alphatec Holdings, Inc. chief financial officer John Todd Koning reported multiple equity awards dated February 25, 2026. He was credited with 205,094 restricted stock units tied to a performance-based award for the fiscal year ended December 31, 2025, vesting in three equal installments on March 5, 2026, March 5, 2027, and March 5, 2028.
He also received 110,394 additional RSUs vesting in three equal installments on March 5, 2027, March 5, 2028, and March 5, 2029, and 20,380 RSUs granted instead of a portion of his 2025 cash bonus, vesting on December 4, 2026. The filing notes forfeiture of 32,403 previously reported RSUs for not meeting performance criteria and awards of up to 55,197 performance-based RSUs that vest only if specified stock price and operational metrics are achieved by dates through December 31, 2030.
Lish Scott reported acquisition or exercise transactions in this Form 4 filing.
Alphatec Holdings, Inc. chief operating officer Scott Lish reported several equity awards on February 25, 2026. He received 311,110 restricted stock units tied to previously set 2025 performance goals, 127,378 time-based RSUs, and 20,992 RSUs granted in lieu of part of his 2025 cash bonus. He also received performance-based RSU awards of up to 63,689 units that vest only if Alphatec’s stock reaches 30-day average prices of $25 or $36 per share or specific operational targets are achieved by dates through 2030. These are stock grants, not open-market share purchases or sales.
Hunsaker Craig E reported acquisition or exercise transactions in this Form 4 filing.
Alphatec Holdings EVP Craig E. Hunsaker reported multiple equity grants from the company. On February 25, 2026, he was awarded 311,110 restricted stock units tied to a prior performance-based award, vesting in three equal installments on March 5 of 2026, 2027, and 2028.
He also received 127,378 RSUs vesting in three installments on March 5 of 2027, 2028, and 2029, plus 20,992 RSUs granted in lieu of part of his 2025 cash bonus that vest on December 4, 2026.
In addition, Hunsaker was granted performance-based awards of up to 63,689 RSUs, which vest only if Alphatec’s stock reaches 30‑day average prices of $25.00 or $36.00 by specified dates, or if certain operational metrics are met as of December 31, 2028 or December 31, 2030.
Miles Patrick reported acquisition or exercise transactions in this Form 4 filing.
Alphatec Holdings CEO Patrick Miles reported multiple equity awards dated February 25, 2026. He received 611,673 restricted stock units (RSUs) tied to a performance-based award originally granted January 29, 2025, after confirmation that performance goals for the year ended December 31, 2025 were met. These RSUs vest in three equal installments on March 5 of 2026, 2027, and 2028.
He was also granted 305,707 additional RSUs vesting in three equal installments on March 5 of 2027, 2028, and 2029, and 48,913 RSUs in lieu of part of his 2025 cash bonus that vest on December 4, 2026. Separately, he was awarded two performance-based RSU tranches of up to 152,853 units each, which vest only if Alphatec’s stock achieves 30-day average prices of $25.00 or $36.00 per share by specified dates or if certain operational metrics set by the compensation committee are achieved by December 31, 2028 or 2030.
Alphatec Holdings (ATEC) is a spine-focused medical technology company aiming to “be the standard bearer in spine” through clinically distinct, procedure-based solutions. It designs and sells integrated platforms spanning implants, biologics, neuromonitoring, imaging, planning software and emerging navigation/robotics to improve predictability and reproducibility in spine surgery.
For the year ended December 31, 2025, Alphatec generated $764.2 million in total revenue, up $152.6 million, or 25%, from $611.6 million in 2024, driven by broader adoption of approach-specific procedures such as PTP, LTP and deformity offerings. Surgical volume grew 22% and average revenue per surgery increased 4% versus 2024, reflecting deeper surgeon usage as its portfolio expands.
The company’s strategy centers on three pillars: creating clinical distinction through continuous innovation (including the InformatiX platform with EOS imaging and EOS Insight software, SafeOp neuromonitoring and Valence navigation/robotics), compelling surgeon adoption via its ATEC Experience training programs, and elevating distribution by building an exclusive, clinically sophisticated sales network in the U.S. and targeted international markets.
Alphatec Holdings (ATEC) reported strong 2025 growth but remains loss-making on a GAAP basis. Full-year 2025 total revenue rose 25% to $764 million, with GAAP gross margin of 70%. Non-GAAP net income reached $8 million and adjusted EBITDA was $93 million, a 12% margin.
Fourth-quarter 2025 revenue was $213 million with adjusted EBITDA of $33 million, or 16% of revenue, and free cash flow of $8 million. Despite this, GAAP net loss for 2025 was $143 million. Cash and cash equivalents were $161 million at year-end.
For full-year 2026, Alphatec expects revenue to approximate $890 million, about 17% growth, including $805 million of surgical revenue and $85 million of EOS revenue. The company raised adjusted EBITDA guidance to about $134 million, or 15% margin, and anticipates generating at least $20 million of free cash flow.
Alphatec Holdings executive Craig E. Hunsaker exercised multiple stock options and increased his direct ownership. On February 12, 2026, he exercised options for 31,710 shares at $1.93, 120,248 shares at $1.68, 78,249 shares at $2.69, and 20,969 shares at $3.09 per share.
The exercise was handled on a cashless basis, with the issuer withholding 41,105 shares to cover the exercise price and issuing 210,071 shares of common stock to Hunsaker. Following these transactions, he directly owned 1,383,096 shares of Alphatec common stock.
Alphatec Holdings, Inc. executive David Sponsel, EVP of Sales, reported selling 60,425 shares of common stock on February 5, 2026 at a weighted average price of $13.79 per share. The filing states the sales were made under a Rule 10b5-1 trading plan adopted on June 12, 2025 to cover certain tax withholding obligations arising from vested restricted stock units.
After this transaction, Sponsel beneficially owns 349,500 shares of Alphatec common stock, including shares acquired through the company’s employee stock purchase plan and reflecting the forfeiture of some previously reported restricted stock units that did not meet performance criteria.
Alphatec Holdings insider David Sponsel has filed to sell 60,425 shares of common stock under Rule 144. The shares, to be sold through Morgan Stanley Smith Barney on NASDAQ around February 5, 2026, have an aggregate market value of $849,575.50 based on the filing.
The securities to be sold were acquired on February 1, 2026 via 40,418 Performance Stock Units and 20,007 Restricted Stock Units granted by the issuer. The notice also reports past 3‑month sales of 21,106 and 988 common shares, including 10b5‑1 plan sales for David Sponsel.